Background Previous studies reported no increase in the prevalence of adverse pregnancy
outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if …

Background Our aim was to estimate and compare the prevalence of adverse pregnancy
outcomes among pregnant women with multiple sclerosis (MS) exposed to interferon beta …

Background: Previous studies showed no increased risk of interferon beta use before or
early in pregnancy among women with multiple sclerosis (MS). However, knowledge about …

Background: Women with multiple sclerosis (MS) are often diagnosed/treated at
childbearing age. Until recently, data on MS and interferon beta (IFNβ) exposure during …

Objectives: To determine the prevalence of categorical measures of birth weight for
gestational age (small for gestational age (SGA), large for gestational age (LGA)), low birth …

Background Family planning is an important consideration for women with multiple sclerosis
(MS), who are often diagnosed during their reproductive years. Currently, limited data are …

Background: Available data suggest that pregnancy exposure to interferon-beta might result
in lower mean birth weight and preterm birth. Objective: To determine the effect of interferon …

Background Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis
(MS). Current guidelines recommend cessation of treatment during pregnancy, however the …

Objective: To assess pregnancy and fetal outcomes after in utero exposure to interferon-β
(IFNβ) in all pregnancies occurring in women with multiple sclerosis (MS) during the study …

Objective There exist controversial and discrepant results on the risk of spontaneous
abortions and teratogenesis induced by interferon treatment in people with MS. Aim of this …